Synaptogenix, Inc. (SNPX)

Market Cap	3.59M
Revenue (ttm)	n/a
Net Income (ttm)	-9.13M
Shares Out	1.36M
EPS (ttm)	-8.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,387
Open	2.510
Previous Close	2.460
Day's Range	2.466 - 2.651
52-Week Range	2.320 - 8.780
Beta	1.43
Analysts	Strong Buy
Price Target	14.00 (+428.1%)
Earnings Date	Nov 12, 2024

About SNPX

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: SNPX
• Website: https://www.synaptogen.com

Analyst Forecast

According to one analyst, the rating for SNPX stock is "Strong Buy" and the 12-month stock price forecast is $14.0.

Price Target

$14.0

(428.10% upside)

Analyst Consensus: Strong Buy